Posted by Michael Wonder on 31 Oct 2023
FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
31 October 2023 - FDA approval based on robust Phase III data in which Cosentyx (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa as early as Week 2.
Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US FDA has approved Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa in adults.
